HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Firm's Supplement Claims For Hangover Relief Watered Down In Industry Self-Regulation Review

Executive Summary

More Labs’ online claims might not be distilled satisfactorily for FDA’s taste for dietary supplement claims for hangover help agency made known a year ago. Firm will narrow claim suggesting its products could broadly relieve hangover symptoms.

You may also be interested in...



Hangover Cures Might Work, But Evidence Weak – Study

According to a recent systematic review of evidence from randomised placebo-controlled trials, the claimed hangover-reducing effects of traditional herbal medicines and dietary supplement ingredients do have some scientific backing. However, the quality of the evidence is extremely low. 

Hangover Supplement Marketer Tries Again, Targeting Main Causes Of Symptoms

Tomo Labs launches namesake brand supplement containing ingredients targeting the three main causes of hangover symptoms. Currently selling online, it hopes to introduce Tomo in groceries, pharmacies and liquor stores.

‘OMUFA Fee Liable’ Trending In US OTC Drug Industry To Pay For FDA's Monograph Reform

Some firms with sales in nonprescription drug space are exempt from program’s facility fees, but own-label OTC drug marketers aren’t among them. Although FDA allows fee discounts for small businesses in other areas, it’s not trimming monograph user fee rates.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel